One of the characteristic features of asthma is chronic airway inflammation typically with eosinophil infiltration. Most asthmatics can be treated successfully with conventional treatment appropriate for their severity, but in some severe cases, asthma cannot be well controlled even with thorough treatment and this condition is known as 'refractory asthma'. 
Introduction
Asthma is a disorder characterized by reversible airway obstruction, airway hyper-responsiveness and chronic airway inflammation typically with eosinophil infiltration. For the majority of asthmatics, asthma can be controlled with conventional treatment appropriate for their severity. However, some types of asthma, known as 'refractory asthma', do not respond to high doses of inhaled corticosteroids (ICS) in combination with long-acting β 2 agonists (LABA), leukotriene receptor antagonists (LTRA) and/or sustained-release theophylline (SRT) and, therefore, are poorly controlled.
The fact that approximately three-quarters of patients with asthma are positive for IgE antibodies against house dust mite suggests that allergic reactions play an important role in the onset of airway inflammation and asthmatic symptoms, regardless of the severity of asthma. As a biological preparation developed in this context, humanized anti-human IgE antibody (anti-IgE; omalizumab) has proved to be effective in treating refractory allergic asthma. Following anti-IgE, humanized anti-human IL-5 antibody (anti-IL-5; mepolizumab) was launched in June 2016 and has provided momentum to the development of biological preparations. This article will focus on biological preparations, mainly anti-IgE and anti-IL-5, for treating asthma and discuss the current status of their developments and problems still to be addressed.
Pathological mechanisms of asthma
In addition to the reversible airway obstruction ranging over different grades of severity and increased airway sensitivity, chronic airway inflammation represents an important target in the treatment for asthma.
Asthma and allergy

Since Ishizaka et al. discovered IgE in 1966 [reviewed in ref.
(1)], research on allergies, which had remained stagnant until then, has made dramatic progress along with the progress in immunology. A lot of evidence has been accumulated to reveal that house dust mite is especially important as a causative antigen of allergy, i.e. an allergen, and to confirm strong association between asthma and IgE (2, 3) .
In addition to the production of IgE antibodies, which is a type of immune response, the allergic reactions include release of inflammatory mediators from mast cells induced by antigen-antibody reactions, the actions of released inflammatory mediators on target organs and the activation of effector and pro-inflammatory cells, resulting in subsequent airway inflammation and remodeling as well as airway obstruction in the case of asthma with various phenotypes. Efforts to understand pathological mechanisms underlying asthma have been clarifying the various cells and cytokines involved in the mechanisms (Fig. 1) (4) . Focusing on different molecules involved in the complex pathological processes has helped identify the molecular targets that would lead to a new therapeutic strategy for asthma ( Fig. 2) 
(5).
Production and function of IgE
To differentiate B cells into IgE antibody-producing cells, two types of signals are required. The first signal is originated from T h 2-type cytokines, i.e. IL-4 and IL-13. This signal promotes gene transcription of IgE antibodies (6, 7) . The second signal comes from the binding of cluster of differentiation 40 (CD40) expressed on the surface of B cells with its ligand (CD40L) located on the surface of activated T h cells, mast cells and basophils (8) . Cytokines, including IL-4, IL-6, IL-9 and TNF-α, are reported to be capable of promoting IgE production. IFN-α, IFN-γ, TGF-β, IL-8, IL-12 and IL-18 have been identified as factors that may suppress IgE biosynthesis (9) .
Mast cells are indispensable for the functioning of IgE antibodies. IgE antibody is a ligand for the high-affinity receptor (FcεRI) on mast cells and, to enable its function, it is bound to FcεRI through the third constant domain of IgE antibody (Cε3) located in the heavy chain (H chain) (10). . The IgE antibody is a ligand for high-affinity receptor (FcεRI) on mast cells, which are capable of releasing not only inflammatory mediators but also pro-inflammatory cytokines and are involved in allergic inflammation as shown in Fig. 3 . IL-5 is the major cytokine for eosinophils to be activated to release inflammatory granular proteins including major basic protein (MBP), eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) to induce eosinophilic airway inflammation and airway remodeling. In addition to the pathway of the acquired immunological response, new pathways via the innate immune system were identified as IgE-independent pathways for eosinophilic inflammation. One is activation of T h 2 cells through IL-33 and TSLP mainly derived from airway epithelial cells that are activated by viruses or other stimuli. Another one is involvement of activated ILC2, which can produce significant amounts of IL-5 and IL-13 comparable with T h 2 cells. It was also recognized that very late antigen-4 (VLA-4) on eosinophils could promote extravascular migration of activated eosinophils via integrin receptors on vascular endothelial cells such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Regarding airway remodeling, TGF-β, insulin-like growth factor I (IGF-I) and platelet-derived growth factor (PDGF) produced by myofibroblasts beneath the basement membrane (BM) as well as macrophages are involved. Moreover, repeated smooth-muscle (SM) constriction can also induce airway remodeling. This original drawing was derived by referring to Figs 4-2 of the JGL 2015 guidelines (4).
Involvement of T h 2 cells
Infiltration and activation of T h 2 cells in the respiratory tract are observed in patients with asthma, regardless of the involvement of allergy. Activation of T h 2 cells through IL-33 (11, 12) and thymic stromal lymphopoietin (TSLP) (13) , both of which are mainly derived from airway epithelial cells, and production of IL-5 and IL-13, both of which are T h 2 cytokines, via activation of type 2 (or group 2) innate lymphoid cells (ILC2) (14) , have been identified as IgE-independent pathways ( 
Biological preparations for asthma
Humanized anti-human IgE antibody
The term 'humanized antibody' refers to an antibody whose function originates from mouse monoclonal antibody recognizing a certain human protein epitope but whose whole sequence except for the antigen-specific binding site is replaced, by human recombinant technology, with the molecular structure of a human immunoglobulin. Theoretically, the antibody, thus, humanized will not be recognized as a heterologous protein even when it is introduced into a human body. The currently marketed anti-IgE is known as omalizumab. The preparation is based on a mouse monoclonal antibody specific to human IgE Cε3, which is a binding site for IgE receptors (FcεRI and FcεRII), and 95% of omalizumab protein sequences, except the human IgE Cε3-specific binding site, are replaced with those of the molecular structure of human IgG1κ by human recombinant technology (16) .
Mechanisms of action.
Anti-IgE binds to Cε3 of the IgE protein and blocks IgE from binding to FcεRI located on the surface of mast cells and basophils (17) . Even if antigen exposure occurs, a series of reactions through IgE involving mast cells are blocked to suppress asthmatic symptoms caused by allergic reactions (Fig. 3) . Anti-IgE inhibits allergens from binding to the IgE already binding to FcεRI on mast cells and basophils by making the condition in which free IgE, i.e. IgE not binding to FcεRI and circulating in the blood stream, captures allergens prior to their reaching IgE on the cells. Moreover, since the half-life of free IgE existing as an immune complex with anti-IgE is about 14 days as compared with that of IgE alone, which is 1-2 days, this inhibitory effect with free IgE may last longer.
In addition, anti-IgE is likely to inhibit FcεRI expression since it binds to Cε3 of circulating IgE, resulting in a reduction in the level of IgE capable of binding to FcεRI whose expression is known to depend on the amounts of the ligand. This inhibitory effect on FcεRI expression is expected to appear first among the various effects of anti-IgE. Indeed, 50% of FcεRI expression was inhibited 3 days after anti-IgE administration, and the number of FcεRI on the surface of basophils decreased from ~200 000 to 8000 per cell, i.e. a 96% reduction, 90 days after administration (18) .
In recent years, anti-IgE therapy has been shown to reduce the total IgE level, which attracts attention as an unexpected beneficial effect of anti-IgE (19) . Additionally, although it has not been supported by evidence, we hypothesize that anti-IgE could affect airway inflammation in asthma by suppressing function of pro-inflammatory cells including eosinophils and lymphocytes, which could be activated by IgE binding to FcεRII, a low-affinity receptor for IgE, on their surface, when anti-IgE blocks binding of IgE to FcεRII on the cells which are involved in the pathogenesis of asthma.
The influence of polymorphisms of several Fc receptors, including FcεRI and FcγRIIIA, on the efficacy of therapies with monoclonal antibodies has not been studied.
Clinical effects.
A randomized double-blind phase 3 study was conducted in Europe and the USA to determine the efficacy of anti-IgE (omalizumab). The test product, anti-IgE, was subcutaneously administered in a manner similar to its future marketed version every 2 weeks or every 4 weeks over 28 weeks depending on the dose of anti-IgE, which was determined in the range of 150-750 mg according to body weight and serum IgE levels. During administration of anti-IgE, beclomethasone dipropionate, a kind of ICS, was reduced, and the frequency of deterioration of asthma symptoms was evaluated as a primary endpoint. The study showed that number of exacerbations as well as 'as-needed' administrations of β 2 agonists and the doses of ICS decreased by the administration of anti-IgE in 268 of 525 patients in the USA (20) and 274 of 546 patients in Europe (21). It did not result in any serious adverse events and their incidence was comparable with the placebo group.
In order to confirm the indication of anti-IgE in severe intractable asthma, sub-analysis was conducted by selecting a high-risk group from the above mentioned phase 3 study. The high-risk group included 254 patients with severe allergic asthma (135 patients treated with anti-IgE and 119 patients treated with placebo) who had a history of endotracheal intubation, emergency visits, hospitalization or treatment at an intensive care unit within the previous year (22) . The primary end-point for this study was the frequency of deteriorating episodes that required an increased ICS dose up to double or systemic administration of corticosteroids. The frequency was converted into a value over 1 year. The high-risk group treated with anti-IgE had a statistically significant reduction in deteriorating episodes and achieved statistically significant improvement in the morning peak expiratory flow (mPEF), asthma symptom score and quality of life (QOL), as compared with the overall anti-IgE group. The study suggests beneficial effects and usefulness of anti-IgE therapy in the high-risk group with severe asthma.
Anti-IgE has also been marketed in Japan under the brand name Xolair® for adults since 2009 and for children since 2012. In order to get permission for launching, a phase 3 randomized, double-blind controlled study was conducted in 315 patients with moderate-to-severe persistent allergic asthma whose condition was poorly controlled even with a high dose of ICS in combination with one or more controllers (LABA, LTRA and SRT). As a result, 151 patients treated with anti-IgE showed significant improvement in mPEF (Fig. 4) and a significant reduction in exacerbation frequency (23) , which were comparable with the data reported globally in the past. controllers, including LABA, LTRA and SRT (Table 1) (24) . Anti-IgE has been administered to ~3000 patients in Japan to date. The updated information from the post-marketing surveillance indicates that ~60% of the patients definitively responded to omalizumab.
The total serum IgE level and body weight of a patient are used to determine the doses, and the range of the total serum IgE levels that allowed eligibility for omalizumab administration was extended from 30~700 IU ml −1 and from 30~1500 IU ml −1 in 2012. Inasmuch as anti-IgE therapy is very expensive, we have been asking whether anti-IgE therapy can be tapered or stopped at a certain time after having beneficial effects. There is a study following up 18 asthmatics for 3 years after a 6-year treatment period with the anti-IgE. As results, 12-16 patients showed sustained therapeutic effects in terms of asthmatic symptoms, nocturnal asthma attacks or maintenance medication (25) , suggesting a possibility of dose reduction or treatment withdrawal at an appropriate time by discovering biomarker(s) for judgment. The other thing we need to find out is a way to distinguish potential responders from nonresponders prior to starting anti-IgE therapy. A recent study showed that asthmatics who responded to anti-IgE therapy had fractional exhaled nitric oxide (FeNO) ≥19.5 ppb (P = 0.001 compared with non-responders), peripheral blood eosinophil count ≥260 µl −1 (P = 0.005) and serum periostin ≥50 ng ml −1 (P = 0.07) (26) . Obviously, further investigation is required to get more firm conclusions on these matters.
Humanized anti-human IL-5 antibody
Airway inflammation plays a pivotal role in the pathogenesis of asthma and is characterized by eosinophilic infiltration induced by activation of eosinophils ( Fig. 1) (4) . IL-5, the most specific and powerful T h 2 cytokine for eosinophils, is produced by T h 2 and ILC2 cells and induces differentiation, growth, activation and prolonged survival of eosinophils (Fig. 2) (5) . The anti-human IL-5 antibody (anti-IL-5) is a humanized monoclonal antibody known as mepolizumab, launched in June 2016 in Japan under the brand name Nucala®. This anti-IL-5, which is derived from mouse monoclonal antibody with high specificity and affinity to human IL-5, is produced in Chinese hamster ovary cells and is humanized with human IgG1κ by genetic recombination technology.
Mechanism of action.
Anti-IL-5 blocks the binding of IL-5 to the IL-5 receptor α-chain (IL-5Rα) expressed on the surface of eosinophils and inhibits IL-5 from acting on eosinophils (27, 28) . As a result, eosinophilic inflammation is suppressed (Fig. 2) 
(5).
Clinical effects. Anti-IL-5 reduced the eosinophil count in the blood in the initial studies, although it did not inhibit biphasic asthmatic response and airway hyper-responsiveness in an antigen inhalation study (29) . However, studies focusing on blood eosinophil count as reference revealed the efficacy of anti-IL-5 to obtain permission for its launching. A phase 3 study included severe asthmatics, who were treated with a high dose of ICS in combination with one or more additional controllers and had an eosinophil count of at least 150 cells µl −1 in the peripheral blood at screening or at least 300 cells µl −1 at some time during the previous year. The patients (n = 539) were randomly assigned to receive anti-IL-5 (mepolizumab), which was administered as a 75-mg intravenous dose (n = 175) or a 100-mg subcutaneous dose (n = 185), or placebo (n = 179). In this phase 3 double-blind, doubledummy study, the primary end-point was the rate of exacerbations and other outcomes that consisted of the forced expiratory volume in 1 s (FEV 1 ) at 32 weeks and scores of QOL. As compared with placebo, subcutaneous administration, which is approved clinically, reduced exacerbations by 53%, increased FEV 1 by 98 ml and improved QOL (30) .
Another randomized, double-blind trial was conducted in patients with severe asthma who had the same peripheral blood eosinophil level as the former study mentioned above and at least a 6-month history of treatment with oral glucocorticoids at Fig. 4 . Effect of anti-IgE in a Japanese population: increase in morning PEF. A phase 3 randomized, double-blind controlled study was conducted in 315 Japanese patients with moderate-to-severe persistent allergic asthma whose condition was poorly controlled even with a high dose of ICS in combination with one or more controllers (LABA, LTRA and SRT). As shown, 151 patients treated with anti-IgE showed significant improvement as much as 13. 5-35 mg per day. It showed that subcutaneous administration of 100 mg anti-IL-5 (n = 66) had a 2.35-fold higher probability of reducing oral dose of corticosteroids than placebo (n = 62) (31). Significant reduction in exacerbation and improvement in asthma control were also observed.
The safety profile of mepolizumab in the above-mentioned studies was similar to that of placebo.
Future prospects. As compared with anti-IgE, which is limited to patients who have a specified total IgE level and are IgE-positive for perennial inhaled antigens, anti-IL-5 is free from any administration limitations. But it is recommended to select patients considering their eosinophil levels for the use of the indicated preparation by considering the better outcomes in patients with somewhat higher eosinophil levels in clinical studies. The dose of anti-IL-5 need not be individualized as in the case of omalizumab (anti-IgE), which requires dose adjustment considering the body weight and total serum IgE level of each patient. Anti-IL-5 may have efficacy in patients with severe asthma for whom anti-IgE antibody is not indicated or effective. It is a new promising medication for asthma with a wide range of severity. Additionally, previous clinical studies showed that anti-IL-5 may have an effect of reducing nasal polyps associated with asthma, which suggests that the product may be effective in treating diseases other than asthma, such as eosinophilic sinusitis, otitis media and eosinophilic granulomatosis with polyangiitis (previously known as 'Churg-Strauss syndrome'), in which eosinophils are functionally involved without any doubt.
Biologics currently under development
According to the pathological mechanisms of asthma ( Fig. 1) (4) , various cytokines may act as target molecules for treating asthma (Fig. 2) (5) . There is another approach to eliminate eosinophils with humanized, afucosylated, anti-IL-5Rα monoclonal antibody (anti-IL-5Rα; benralizumab) via enhanced antibody-dependent cell-mediated cytotoxicity, which induced direct, rapid and nearly complete depletion of eosinophils. Anti-IL-5Rα significantly reduced rates of annual exacerbation for uncontrolled asthmatics with ≥300 blood eosinophils µl −1 (32) . In addition to anti-IL-5Rα, a recombinant fully human monoclonal antibody to IL-4 receptor α-chain (anti-IL-4Rα; dupilumab) was developed and investigated by a phase 2A randomized, double-blind, placebo-controlled trial. Since the IL-4Rα is a receptor shared by both IL-4 and IL-13, anti-IL4Rα can inhibit signaling of IL-4 and IL-13 and was reported to decrease asthma exacerbations even with withdrawal of LABAs and ICS, improved pulmonary function, i.e. FEV 1 , morning and evening PEF and decreased levels of T h 2-associated markers, i.e. blood eosinophil count, levels of IgE, FeNO, thymus and activation-regulated chemokine (TARC), plasma eotaxin-3 and so forth (33) . TSLP (34) and IL-33 (35) , which are involved in the pathways of the innate immune system, have also attracted attention. Furthermore, research to explore new therapeutic agents targeting molecules for intracellular signal transduction systems and transcription factors beyond allergic therapeutics is also ongoing to develop new biological preparations. Concomitantly use one or more of the agents below:
Concomitantly use multiple agents from those below:
• LTRA • Theophylline sustainedrelease preparation (unnecessary for rare symptoms)
• LABA (a compounding agent can be used) In patients treated with a combination of budesonide/formoterol as a controller, if used as a rescue, the agent should not be used beyond the maximum number of uses per time and per day. The maximum number of uses is generally up to eight inhalations per day; however, temporarily, it can be used up to 12 inhalations per day (for 3 days: budesonide, 1920 µg per day; formoterol 54 µg per day). When more than eight inhalations per day of budesonide/formoterol are needed, a physician should be consulted. 
Conclusion
Novel strategies with biologics targeting eosinophilic airway inflammation discussed in this review will provide a vast array for us to overcome severe refractory asthma in the future.
